LONDON, UK. March 30th, 2026 – Fertility testing in the UK is starting to look very different. Instead of multiple appointments, referrals, and weeks of waiting, a new model is emerging where both partners can test at home, at the same time, and walk into their first clinic appointment with answers already in hand.
Sapyen, a fertility diagnostics company used by leading IVF clinics such as Avenues, has launched a combined at-home testing suite that brings together male fertility hormone testing, female AMH testing, and laboratory semen analysis into a single, coordinated workflow.
The offering is straightforward. A male fertility hormone panel measures key markers including testosterone, FSH and LH. A female AMH test provides an early view of ovarian reserve. Both are priced at £69. These can be paired with Sapyen’s semen analysis, priced at £149, which is conducted in a laboratory following at-home collection.
What makes the approach notable is not the individual tests, but how they are used together. For the first time, couples can complete a clinically meaningful fertility assessment before stepping into a consultation. Instead of beginning with questions, they begin with data.
That shift has immediate implications. Fertility pathways are often slowed by fragmented testing and delayed male engagement. By bringing both partners into the process from day one, clinicians are able to move more quickly from investigation to decision-making.
The male component is particularly significant. While male factors contribute to roughly half of infertility cases, testing has historically focused on sperm alone. By combining semen analysis with hormone testing, the model captures both sperm quality and the underlying endocrine signals that influence it, offering a more complete view of male reproductive health.
On the female side, AMH testing provides an early signal that can shape timelines and expectations before treatment decisions are made. Underpinning the system is Sapyen’s ability to transport semen samples to laboratories without the traditional time constraints, allowing at-home collection without compromising analysis.
For clinics, adoption is designed to be seamless. Results are delivered in standard clinical formats and can be integrated into existing workflows without additional infrastructure. For patients, the experience is simpler and faster, with fewer points of friction.
The result is a different starting point for fertility care. One where couples test together. One where clinicians see the full picture earlier. And one where the path forward becomes clearer from the very first appointment.
ENDS